Chordia Therapeutics (TSE:190A) - Stock Price, News & Analysis

190A Stock Overview

A biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan.

About the company

190A fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Has not reported any financial data

Highly volatile share price over the past 3 months

Chordia Therapeutics Inc. Competitors

Cuorips

TSE:4894

JP¥65.0b

SanBio

TSE:4592

JP¥71.8b

Pharma Foods International

TSE:2929

JP¥26.4b

StemRIM

TSE:4599

JP¥26.9b

Price History & Performance

Summary of all time highs, changes and price drops for Chordia Therapeutics
Historical stock prices
Current Share Price	JP¥780.00
52 Week High	JP¥930.00
52 Week Low	JP¥142.00
Beta	0
11 Month Change	43.12%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	306.25%

Recent updates

Shareholder Returns

	190A	JP Biotechs	JP Market
7D	4.8%	6.4%	0.9%
1Y	n/a	5.1%	13.7%

Return vs Industry: Insufficient data to determine how 190A performed against the JP Biotechs industry.

Return vs Market: Insufficient data to determine how 190A performed against the JP Market.

Price Volatility

Is 190A's price volatile compared to industry and market?
190A volatility
190A Average Weekly Movement	24.0%
Biotechs Industry Average Movement	13.5%
Market Average Movement	6.3%
10% most volatile stocks in JP Market	10.1%
10% least volatile stocks in JP Market	3.4%

Stable Share Price: 190A's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 190A's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2017	n/a	Hiroshi Miyake	www.chordiatherapeutics.com

Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. The company was incorporated in 2017 and is based in Fujisawa, Japan.

Chordia Therapeutics Inc. Fundamentals Summary

How do Chordia Therapeutics's earnings and revenue compare to its market cap?
190A fundamental statistics
Market cap	JP¥51.53b
Earnings (TTM)	JP¥0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is 190A overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
190A income statement (TTM)
Revenue	JP¥0
Cost of Revenue	JP¥0
Gross Profit	JP¥0
Other Expenses	JP¥0
Earnings	JP¥0

Last Reported Earnings

n/a

Next Earnings Date

Oct 11, 2024

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did 190A perform over the long term?

See historical performance and comparison

Chordia Therapeutics TSE:190A Stock Report